OBJECTIVE The predictive value of five risk score models containing clinical (PAMI-PMS, GRACE-GRS, and modified ACEF-ACEFm-scores), angiographic SYNTAX score (SXS) and combined Clinical SYNTAX score (CSS) variables were evaluated for the incidence of three procedural complications of primary percutaneous coronary intervention (pPCI): iatrogenic coronary artery dissection, angiographically visib...

BACKGROUND No-reflow phenomenon after percutaneous coronary intervention (PCI) in patients with acute ST-segment-elevation myocardial infarction (STEMI) is relatively common and has therapeutic and prognostic implications. Cigarette smoking is known as deleterious in patients with coronary artery disease (CAD), but the effect of smoking on no-reflow phenomenon is less investigated. The aim of t...

PURPOSE Despite successful restoration of blood flow in epicardial artery after myocardial infarction (MI), some patients do not benefit sufficiently from modern revascularisation methods due to the impairment of microcirculation, also called no-reflow phenomenon. Hyperlipidaemia is well established risk factor of coronary heart disease and its detrimental actions on vessels are widely acknowle...

#### Notable in Neurology This Week issue features an article that examines the association between COVID-19 and risk of acute ischemic stroke; another investigates whether epilepsy type, seizure location, medications influence frequency during pregnancy postpartum. A featured Contemporary Issues Practice, Education, & Research explores strategies to generate more interest neurology among under...

Objectives: The goal of this study was to evaluate the long-term safety and efficacy of intracoronary epinephrine in reversing refractory no-reflow during primary percutaneous coronary intervention (PCI). Methods: A total of 248 consecutive patients with acute myocardial infarction who had been treated from September 2009 to November 2010 at the Cardiology Department of Turkiye Yuksek Ihtisas H...

It has been verified that glycoprotein IIb/IIIa inhibitor tirofiban can attenuate myocardial no-reflow. Myocardial no-reflow has been associated with alterations in endothelial junctions. In addition, ET-1 is an important mechanism for myocardial no-reflow. However, the effect of tirofiban on endothelial junctions and Endothelin-1 (ET-1) is unknown. Methods: Twenty-eight mini-swines were random...

INTRODUCTION The determinants of clinical outcomes in patients with acute ST-elevation myocardial infarction (STEMI) are still being debated. The aim of this study was to investigate the prognostic value of the no-reflow phenomenon and epicardial adipose tissue (EAT) thickness for clinical outcomes in patients undergoing primary percutaneous coronary intervention (pPCI) for STEMI. METHODS The...

Abstract Introduction The no-reflow phenomenon is a serious complication of coronary intervention, especially in primary angioplasty and effective preventive measures are unknown. Methods Retrospective study all patients treated by single center through 4 years. We define as the absence flow immediately after stent angioplasty. variables associated with this were analyzed using binary logistic ...